Characterization of VIP- and helodermin-preferring receptors on human small cell lung carcinoma cell lines

Peptides. 1990 Nov-Dec;11(6):1239-44. doi: 10.1016/0196-9781(90)90158-2.


We investigated the molecular and pharmacologic characteristics of VIP receptors on two human SCLC cell lines: NCI-N592 and NCI-H345. With NCI-N592 cell, the order of potency of VIP-related peptides in inhibiting 125I-VIP binding and in stimulating cAMP production was typical of the human VIP receptor. By covalent cross-linking, a polypeptide of Mr 62,300 was obtained. Conversely, the behavior of NCI-H345 cell line was totally different: helodermin was the most potent peptide, VIP and PHI were equipotent, while hGRF and secretin were totally ineffective. These results suggest that NCI-N592 cells possess a typical VIP receptor while NCI-H345 cells possess a helodermin-preferring receptor, and that the natural target of helodermin might not be the VIP receptor.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Carcinoma, Small Cell / metabolism*
  • Cell Membrane / metabolism
  • Cross-Linking Reagents
  • Cyclic AMP / metabolism
  • Electrophoresis, Polyacrylamide Gel
  • Humans
  • Intercellular Signaling Peptides and Proteins
  • Iodine Radioisotopes
  • Lung Neoplasms / metabolism*
  • Peptides*
  • Receptors, Cell Surface / chemistry*
  • Receptors, Gastrointestinal Hormone / chemistry*
  • Receptors, Gastrointestinal Hormone / metabolism
  • Receptors, Neuropeptide*
  • Receptors, Vasoactive Intestinal Peptide
  • Tumor Cells, Cultured
  • Vasoactive Intestinal Peptide / metabolism*


  • Cross-Linking Reagents
  • Intercellular Signaling Peptides and Proteins
  • Iodine Radioisotopes
  • Peptides
  • Receptors, Cell Surface
  • Receptors, Gastrointestinal Hormone
  • Receptors, Neuropeptide
  • Receptors, Vasoactive Intestinal Peptide
  • helodermin receptor
  • Vasoactive Intestinal Peptide
  • heliodermin
  • Cyclic AMP